On-demand from the European Academy of Neurology 2025 Satellite Symposium, please enjoy this educational session provided by global experts in the field of generalized myasthenia gravis – Prof. Francesco Saccà (Italy), Prof. Heinz Wiendl (Germany), & Prof. Elena Saccani (Italy).

Symposium Objectives

• Explore long-term evidence for the efficacy and safety of ravulizumab and eculizumab as treatments for anti-acetylcholine receptor antibody-positive (AChR-Ab+) gMG in clinical trial and real-world settings
• Review current guidelines and unmet needs in gMG treatment
• Discuss real-world experience for patients being treated with biologics
• Review challenges that patients experience as they navigate diagnosis and treatment

SOLIRIS^® (eculizumab) is indicated for the treatment of refractory generalised myasthenia gravis (gMG) in patients aged 6 years and above who are anti-acetylcholine receptor (AChR) antibody-positive.

ULTOMIRIS^® (ravulizumab) is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody-positive.

Ravulizumab EU Summary of Product Characteristics
Eculizumab EU Summary of Product Characteristics

Prescribing information may differ from country to country. Please refer to your locally approved label and take this into consideration when viewing this information.

Please verify reimbursement status applicable in your country.

Healthcare professionals are asked to report any suspected adverse reactions. Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following email: https://contactazmedical.astrazeneca.com/